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Purpose: Due to the potentially periodic collimator dynamic in volumetric modulated arc therapy
(VMAT) dose deliveries with the sweeping-window arc therapy (SWAT) technique, additional mani-
festations of dosimetric deviations in the presence of intrafractional motion may occur. With a fast
multileaf collimator (MLC), and a flattening filter free dose delivery, treatment times close to 60 s per
fraction are clinical reality. For these treatment sequences, the human breathing period can be close to
the collimator sweeping period. Compared to a random arrangement of the segments, this will cause
a further degradation of the dose homogeneity.
Methods: Fifty VMAT sequences of potentially moving target volumes were delivered on a two
dimensional ionization chamber array. In order to detect interplay effects along all three coordinate
axes, time resolved measurements were performed twice—with the detector aligned in vertical (V)
or horizontal (H) orientation. All dose matrices were then moved within a simulation software by
a time-dependent motion vector. The minimum relative equivalent uniform dose EUDr,m for all
breathing starting phases was determined for each amplitude and period. Furthermore, an estimation
of periods with minimum EUD was performed. Additionally, LINAC logfiles were recorded during
plan delivery. The MLC, jaw, gantry angle, and monitor unit settings were continuously saved and
used to calculate the correlation coefficient between the target motion and the dose weighed collimator
motion component for each direction (CC, LR, AP) separately.
Results: The resulting EUDr,m were EUDr,m(CCV)= (98.3±0.6)%, EUDr,m(CCH)= (98.6±0.5)%,
EUDr,m(APV)= (97.7±0.9)%, and EUDr,m(LRH)= (97.8±0.9)%. The overall minimum relative
EUD observed for 360◦ arc midventilation treatments was 94.6%. The treatment plan with the shortest
period and a minimum relative EUD of less than 97% was found at T = 6.1 s. For a partial 120◦ arc,
an EUDr,m= 92.0% was found. In all cases, a correlation coefficient above 0.5 corresponded to a
minimum in EUD.
Conclusions: With the advent of fast VMAT delivery techniques, nonrobust treatment sequences for
human breathing patterns can be generated. These sequences are characterized by a large correlation
coefficient between a target motion component and the corresponding collimator dynamic. By
iteratively decreasing the maximum allowed dose rate, a low correlation coefficient and conse-
quentially a robust treatment sequence are ensured. C 2015 Author(s). All article content, except
where otherwise noted, is licensed under a Creative Commons Attribution 3.0 Unported License.
[http://dx.doi.org/10.1118/1.4914166]
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1. INTRODUCTION
Delivering dose to a moving target can potentially degrade the
dose homogeneity in the target volume.1,2 Various strategies
to minimize the relative motion between the treatment beam
and the target volume have been described for volumetric
modulated arc therapy (VMAT):3 The first approach is to
treat the target volume in a static situation by using either
respiratory gated radiation therapy4 or active breath-hold
techniques.5,6 Since these techniques make use of only certain
breathing phases, the treatment time is typically increased.
The second approach is to perform a real-time adaptation of
the multileaf collimator (MLC) aperture depending on the
position of the target volume in beams-eye-view, known as
dynamic multileaf collimator (dMLC) tracking.7–9 While this
approach has great potential to assure a fast and accurate
treatment delivery, real-time information of the target position
may not be available with sufficient accuracy. If neither gating
nor tracking can be applied, treatments have to be performed
in free breathing. For these cases, the resulting dosimetric
effects have been theoretically predicted10–13 and validated
in experiments14–18 and simulations.19–23 Two manifestations
of dosimetric errors have to be considered: dose blurring
and interplay effects. A dose delivery with a static MLC
while the target is moving results in a blurred (smeared
out) dose distribution. A degradation of the resulting dose
distribution in the target volume occurs adjacent to the
gradients of the static dose distribution by the extent of the
motion amplitude. In dose blurring, the expectation value of
the dose in every voxel can be estimated by a convolution
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of the dose distribution without motion and the probability
density function (pdf) of the target motion. Nonrigid organ
motion24 and the changes in radiological depth due to target
motion are not considered in this model (static dose cloud
approximation12). According to the central limit theorem,
every pdf converges to a Gaussian distribution if a sufficient
number of fractions are delivered. Treatment planning in the
presence of a blurred dose distribution is presented in AAPM
report 91.25 The planning target volume (PTV) is obtained by
enlarging the clinical target volume (CTV) with an appropriate
CTV–PTV margin.26
For a dynamic dose delivery, interplay or interference
effects between the linear accelerator’s (LINAC’s) MLC and
the target motion may be present. In contrast to a pure
amplitude determined dose blurring, dosimetric errors can
occur at all segment dose gradients within the target volume.
Therefore, the pdf of a voxel no longer equals the pdf of the
entire motion pattern. It has to be modified to only include
the time intervals where a beam is actually contributing to the
dose in the voxel. The structure of the temporo-spatial delivery
pattern will have the highest impact when only a small number
of fractions are delivered in combination with a fast, highly
modulated treatment sequence. For these delivery types, a
convergence of the voxel pdf to a Gaussian distribution may
not be warranted.
Sweeping-window arc therapy (SWAT) relies on a change
of the motion direction of the individual MLC leaves after
a constant degree of gantry angle Θ (increment factor
∆Θ). VMAT dose deliveries with the SWAT technique27 are
therefore characterized by a potentially periodic motion of
the collimator.28 This feature allows, on the one hand, for a
good starting condition during the treatment plan optimization
and, on the other hand, it minimizes the amount of MLC leaf
travel. This reduces the treatment time even further, compared
to conventional VMAT. In SWAT, different collimator angles
may be used. While Cameron27 used 90◦ collimator angle and
therefore an MLC leaf motion parallel to the axis of gantry
rotation, Ulrich et al.29 used 0◦ and Otto3 45◦ collimator angle.
Intensity modulation is predominantly performed through
dose rate and leaf speed variation,3 which allows for a close
to constant angular gantry rotation velocity.
Since in VMAT typically one arc is used, the phase
relation cannot change on a beam-to-beam basis, as it is the
case in step-and-shoot or dMLC IMRT treatments. With a
fast MLC, and a flattening filter free (FFF) dose delivery,
treatment times close to 60 s per fraction are clinical reality,30
even for hypofractionated treatments with more than 5 Gy
fraction dose. Since these treatment times contain only few
breathing cycles, an averaging of the breathing pattern gets
less likely and the human breathing period may get close to
the collimator sweeping period. In analogy to the phenomenon
of interference of temporally coherent waves, this may cause
additional dosimetric deviations.
These facts require a further analysis of dosimetric
robustness beyond the observations presented for IMRT.11,12,17
To evaluate motion induced dosimetric artifacts specific to
SWAT, three aspects shall be addressed: First, a method to
quantify dosimetric artifacts in measured dose distributions
in the presence of motion is presented; second, a theoretical
prediction of breathing periods with minimum dose coverage
is made; and third, a sensitive parameter that can be used
to mitigate dosimetric deviations due to intrafractional target
motion is identified and applied.
2. METHODS AND MATERIALS
2.A. Patient and treatment sequence collective
An Elekta (Stockholm, Sweden) Synergy LINAC with
MLCi2 collimator and an Elekta VersaHD LINAC with
Agility MLC were used for treatment sequence delivery.
Treatment plans were generated with the Monaco 3.2/3.3
(Elekta) treatment planning system. Fifty different treatment
plans for 13 different patients with lesions in lung (8), liver
(2), stomach (1) or esophagus (2) were evaluated. Eight
plans were generated using an MLCi2 collimator (fraction
dose Dfx = 2 Gy), 28 plans were generated with an Agility
collimator (Dfx= 1.8–3 Gy), and 14 plans were planned for a
VersaHD LINAC for hypofractionated flattening filter free
treatments (Dfx = 5–12 Gy). All treatment deliveries were
performed with one 360◦ VMAT arc and increment factors
∆Θ between 10◦ and 40◦. The collimator angle was set to
0◦, what resulted in a MLC leaf motion perpendicular to the
axis of gantry rotation. Treatment volumes ranged from 12 to
2273 cm3.
2.B. Estimation of the dose distribution
in the presence of motion
All treatment sequences were delivered on a table-
mounted, two dimensional ionization chamber array (Matri-
XX Evolution, IBA, Schwarzenbruck, Germany) inside a
water equivalent phantom (Multicube Lite, IBA). The dose
was recorded with a sampling time of ∆t = 100 ms and stored
in separate matrices. To be able to detect interplay effects
along the three coordinate axes, all treatment sequences were
delivered on the detector, aligned once in vertical and once
in horizontal direction. A purpose written ® (Natick,
MA) based script package was developed to evaluate the dose
distribution in the presence of target motion. First, every
matrix of the two dimensional measured static dose grid is
interpolated to 2 mm spatial resolution. As shown in Fig. 1, the
individual dose planes are then moved in either craniocaudal
(CC), left–right (LR) or anterior–posterior (AP) direction. The
nonzero component xt of the target motion vector depends
on the time after the start of the delivery t. It is determined
according to Lujan et al.,10








where A is the peak-to-peak amplitude, T the breathing period,
and φ the starting phase with respect to the treatment delivery
start. The asymmetry factor k is in the following set to
k = 1. The amplitude offset −A/2 in Eq. (1) mimics a dose
delivery around midventilation phase. Finally, a summation
of all time dependent dose matrices yields the cumulative
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F. 1. Simulation of the dose distribution in the presence of motion. Individual time dependent dose distributions without target motion (left) and modified by
a sine target motion (right) are shown. The rectangles in the central region represent nonzero dose levels while the rest equals zero dose.
dose distribution in the presence of motion. This procedure
is performed for all 2.13× 105 permutations of the follow-
ing parameter sets: Asim = {0.5 cm, 1.0 cm, 2.0 cm}, Tsim
={1.0 s, 1.1 s, 1.2 s, . . ., 25.0 s}, φsim={0◦, 2.5◦, 5◦, . . ., 177.5◦}
and the four different target motion and detector orientation
combinations: CCH and LRH for horizontal detector alignment
as well as CCV and APV for a vertical detector alignment. In
a second step, the generated cumulative dose distributions are
used to obtain the generalized equivalent uniform dose EUD
(Refs. 31 and 32) as a function of motion amplitude, breathing











The EUD is calculated with a = −25 for all N dose pixels
Dl with more than 70% of the maximum dose of the static
dose distribution. The threshold dose value is motivated by the
following consideration: For measurements in a phantom, the
PTV structure is not available. Therefore, the maximum dose
serves as a reference value. The dose within the target should
be within 95%–107% of the prescription dose.33 Additionally,
the dose distribution in the phantom does not ideally resemble
the dose distribution in the patient which can result in a
further target dose inhomogeneity. Since in the patient the
95% isodose line should cover the PTV outline, a threshold
value lower than 88% of the maximum dose, but still within
the high dose gradient area, should be chosen to assure that
all relevant voxels are being considered.
The factor a in Eq. (2) allows for an explicit selection
of the degree of the minimum dose component (for a =−∞)
or the mean dose component (for a = 1). With the choice of
a = −25, a result close to the minimum ROI dose but still
sufficient dependency on the size of the underdosed volume
is provided.
The minimum relative equivalent uniform dose EUDr,m is
obtained by the ratio of the EUD of the dose slice if motion






The EUDr,m is obtained over all breathing starting phases.
Phase averaged, the relative EUD equates the EUD of a pure
dose blurring case, i.e., without consideration of the temporal
substructure. The static case typically shows a nonuniform
distribution in the target volume. Therefore, to be sensitive to
motion-induced effects, the ratio of dynamic over static dose
distribution was considered.
2.C. Estimation of periods with a minimum EUDr,m
For motion in CC-direction, the jaws, which do not follow
a sweeping window pattern, are the beam limiting devices.
Motion in LR-direction was reported34–36 to be generally less
pronounced than motion in AP-direction. Therefore, for a
collimator angle of 0◦, target motion in AP-direction is most
likely prone to SWAT-specific dosimetric errors and will be
considered in this section.
In the presented model, dosimetric deviations resulting
from target motion parallel to the central beam axis are
neglected, and solely dose gradients along the beam penumbra
are considered. This assumption is motivated by the fact that
for a 6 MV beam with flattening filter and a (5×5) cm2 square
field, the dose gradient along the central axis at 10 cm depth
is dD/dxpdd=−3%/cm of the maximum dose while the mean
gradient between the 20% and the 80% penumbra dose at the
same depth is dD/dxCL=±61%/cm of the maximum dose.
To model a SWAT beam delivery, a treatment sequence
with a sweeping collimator gap that performs s sweeps with an
amplitude Ac and period ttot/s, while the gantry performs one
360◦ considered. The dynamic of the resulting dose gradient
areas is depending on two quantities: the current gantry angle
and the position of the collimator gap. The impact of the
gantry angle on the orientation of the penumbra with respect
to the AP-direction of target motion can be described by a
sine function of the current gantry angle, whereas the periodic
collimator motion is modeled by another sine function. This
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gantry component
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The number of sweeps s is a function of the increment factor
∆Θ: s = 360◦/(2 ·∆Θ) defined during treatment planning. As
a first order approximation for periodic breathing patterns,
the target AP-motion can be assumed to perform a periodic
motion. For k = 1, a constant amplitude A, and ϕ= 2φ+π/2,








In this model, the angular frequency ωt = 2π/T corresponds
to the dominant amplitude square component of any Fourier
transformed irregular motion pattern. It is assumed that in
SWAT, the gantry angle changes with a constant angular
velocity Θ̇= 2π/ttot. Therefore, the gantry angle Θ1 is reached
at t = 1/4 ttot and Θ2 at t = 3/4 ttot.
In order to achieve a maximum dosimetric deviation in the
target volume, the two functions xp and xt have to be both
extremal at Θ1 and Θ2
∂xp
∂t




t=1/4 ttot; 3/4 ttot
= 0 (6)
and both either in-phase (+) or of opposite-phase (−) around









) t=1/4 ttot; 3/4 ttot.
(7)
In the opposite-phase case, the target voxels avoid the beam to
a maximum degree. For a target volume that is larger than the
motion amplitude, this results in an underdosed central target
region and an overdosed peripheral target region along the
motion direction as well as an increased dose deposit outside
the target. In the in-phase scenario, the target voxels follow
the MLC sweep. Therefore, they accumulate more dose in
the central target region while a sufficient target coverage at
peripheral target regions is not guaranteed.
Between Θ1 and Θ2 an integer number of breathing cycles
can take place [T = ttot/(2b), b ∈ N] without changing the
resulting behavior. From the above conditions, it follows that s
has to be a positive, odd integer number. Solving the resulting
system of equations yields for the two free target motion
parameters T and ϕ
T =
1




− Z + p
)
, (9)
with Z ∈ Z and p = 0 for the opposite-phase case and p = 1
for the in-phase case. Equation (8) implies that the periods
of maximum in-phase behavior are identical to the periods of
maximum opposite-phase behavior.
2.D. Analysis of correlated motion patterns in SWAT
During plan delivery, the gantry angle, the cumulative
monitor unit, and the individual MLC and jaw positions
were recorded in LINAC logfiles with a frequency of 4 Hz.
The Pearson correlation coefficient r(xc,xt) for the collimator
position component xc along a specific axis (AP, LR, CC)
and the target motion xt in the same direction for a discrete












where i from 1 to n are the individual discrete times. Parallel to
the direction of MLC leaf motion, this calculation is performed
for all MLC leaves j that are not behind the craniocaudal
jaws. Perpendicular to the direction of MLC leaf motion, the
jaw positions are taken. The maximum correlation coefficient
rmax(A,T) of all relevant leaves or jaws jrel and of all starting










Besides this purely geometrical consideration of the two
dynamic patterns, a weight factor according to the dosimetric
contribution of the segment has to be added. The relative
weight is a product of the number of monitor units nMU
delivered in a time interval and the attenuation factor
ratt(FSequ,d). This factor is the relative dose of an equivalent
square field of size FSequ of the current segment at a depth d.
d is the water equivalent distance traversed between patient or
phantom surface and the beam isocenter. Therefore, the dose













Figure 2 shows an analysis of two representative treatment
sequences. In the upper row, the minimum relative EUD as a
function of the applied breathing period for different peak-to-
peak breathing amplitudes is displayed, while the lower row
shows the corresponding correlation coefficients between a
target motion with A= 2 cm and the collimator dynamic AP-
component. In both cases, motion in AP-direction was applied
with the detector array being positioned in vertical alignment.
The figures in the left column were generated with a treatment
sequence of a target volume in the central right lung and were
delivered with an MLCi2 collimator (ttot= 197 s, ∆Θ= 20◦),
while the figures in the right column represent a treatment
sequence for a target volume in the distal left lung, delivered
with an Agility MLC (ttot= 61 s, ∆Θ= 20◦). The black circles
indicate the predicted EUDr,m period times according to
Sec. 2.C for Z ∈ {−6,−5, . . ., 3}. The minima with the lowest
EUDr,m were found for Z =−5 for both cases. In the presented
cases, the deviations between predicted and measured periods
were (0.01±0.08) s and (−0.04±0.25) s.
In order to avoid high correlation coefficients within the
range of human breathing periods, the maximum allowed
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F. 2. Upper row: Relative maximum equivalent uniform dose EUDr,m(A,T ). Lower row: The corresponding maximum correlation coefficient r (xc, xt). The
presented treatment sequences were delivered with an MLCi2 collimator (left column), ∆Θ= 20◦, ttot= 197 s and an Agility MLC (right column), ∆Θ= 20◦,
ttot= 61 s. The black circles indicate the predicted minima according to Sec. 2.C.
doserate Ḋmax of a treatment sequence can be reduced. The
result of limiting Ḋmax on the periods with maximum cross
correlation is presented in Fig. 3. The correlation coefficient
between a target motion with different (A,T) settings and a
collimator dynamic was obtained for three different Ḋmax:
560, 400, and 270 monitor units per minute. The collimator
dynamic of the left MLC leaf bank of the treatment sequence
presented in Fig. 2 (right) was used for the determination
of the correlation coefficients. For the presented treatment
sequences, the resulting delivery times were 61, 76, and 109 s,
respectively.
A dose delivery with a partial arc can lead to a further
degradation of the dose homogeneity due to less dosimetric
contributions from segments that move parallel to the motion
direction. Therefore, the treatment sequence used in Fig. 2
on the right was limited to gantry angles between 40◦ and
160◦ with an increment of ∆Θ= 20◦. The resulting analysis is
shown in Fig. 4. A correlation coefficient of 0.94 resulted in a
minimum EUDr,m of 92.0%.
F. 3. Correlation coefficients for different maximum dose rates Ḋmax. The
collimator dynamic of the left MLC leaf bank of the treatment sequence
presented in Fig. 2 (right) was used.
In Fig. 5, a measured dose distribution of the Agility MLC
treatment sequence used in Fig. 2 without target motion is
shown on the left. A target motion with T = 6.1 s, A= 2 cm,
and φ = 90◦ (Z = −4) was then applied. The corresponding
dose differences to the static case are shown in Fig. 5 on the
right. While the middle figure was generated with motion in
CC-direction, the right figure was generated with motion in
AP-direction.
The effect described in Sec. 2.C that in the opposite-phase
case, dose from the central PTV regions gets deposited in
peripheral regions due to an opposing motion of MLC leaves
and patient breathing is demonstrated in the right figure.
The dose distributions represented the minimum EUDr,m
of this treatment sequence.
The EUDr,m was determined for all treatment sequences
and the four different motion scenarios. A histogram of the
resulting EUDr,m distribution of all simulated cases was
F. 4. Treatment sequence with a partial arc from 40◦ to 160◦ gantry an-
gle. Upper row: Relative maximum equivalent uniform dose EUDr,m(A,T).
Lower row: Maximum correlation coefficient r (xc, xt).
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F. 5. Left: Measured dose distribution in (Gy) without target motion.
Middle and right: Corresponding dose difference maps in (%) of the static
case when a target motion with T = 6.1 s, A= 2 cm, and φ = 90◦ was applied.
Black arrows indicate the direction of target motion.
created with an EUDr,m bin width of 1%. This distribution is
shown in Fig. 6.
The mean EUDr,m were
• EUDr,m(CCV)= (98.3±0.6)%,
• EUDr,m(CCH)= (98.6±0.5)%,
• EUDr,m(APV)= (97.7±0.9)%, and
• EUDr,m(LRH)= (97.8±0.9)%.
On average, the EUDr,m for the target motion directions
parallel to the MLC leaf motion direction was 0.7% lower
when compared to a target motion perpendicular to the MLC
leaf motion direction.
F. 6. Distribution of the minimum relative EUDr,m values of all treatment
sequences and the different motion directions.
T I. Dependency of the number of sweeps on the minimum relative
EUD.
∆Θ in deg 10 20 25 30 40
Number of sweeps 18.0 9.0 7.2 6.0 4.5
Number of sequences 3 18 3 12 4
EUDr,m(APV) in (%) 97.7 97.0 97.9 98.1 97.5
σ

EUDr,m(APV) in (%) 0.9 0.8 0.8 0.6 0.7
Table I shows the dependency of the applied number of
sweeps on the EUDr,m(APV). Solely, treatment sequences of
target volumes larger than 50 cm3 were considered to ensure
a pronounced sweep behavior. In agreement with the model
presented in Sec. 2.C for 9 sweeps, the EUDr,m(APV) had the
lowest mean value.
4. DISCUSSION
4.A. Suitability of the evaluation method
Various methods to evaluate the effect of target motion
on the resulting dose distribution in IMRT and VMAT, such
as Monte Carlo simulations19 or measurements in suitable
phantoms14,16,18 with representative parameter settings have
been performed. However, in SWAT, an appropriate selection
of the parameters (A,T ,Φ) is crucial for an accurate estimation
of the worst possible treatment sequence. As shown in Fig. 2,
the treatment plan robustness varied for different breathing
periods. Increasing the target motion amplitude on the other
hand showed a similar behavior over the entire period range.
Mean and standard deviations, as well as gamma analysis,8
as measures for dosimetric errors are insensitive if the
deviations affect only a small volume. If one considers
exclusively minimum doses on the other hand the size of
the underdosed volume is not taken into account. DVH based
methods are either multidimensional37 or use volumetric and
dosimetric scalar quantities, such as V50 (%) or D95 (Gy), to
evaluate the data. This kind of evaluation is typically being
performed38 for several dose or volume levels. In order to
be able to observe the explicit dependence of the breathing
period and amplitude on the treatment sequence robustness,
the scalar EUDr,m serves as an appropriate measure.
The Pearson correlation coefficient as presented in Eq. (11)
is a measure of a linear correlation between the target and
collimator motion. Nonlinear behavior will therefore lead
to a reduced maximum correlation coefficient. However, if
a random-like segment order was present, the correlation
coefficient was close to 0 and a relatively low correlation
coefficient threshold of 0.5 was sufficient to detect minima in
EUDr,m for all observed cases.
The use of a solid water phantom as a substitute for
lung tissue will affect the dosimetric outcome. Therefore,
the relative minimum EUD serves in this context more as
a relative measure to indicate nonrobust frequencies than an
absolute measure for the actual target EUD. The same applies
for the choice of the parameter a in Eq. (2). Furthermore, in
this study, solely the dosimetric consequences of a moving
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target on the target volume were considered. In a realistic
patient scenario, a nonrigid organs at risk (OAR) deformation
will additionally affect the OAR doses, as well.
4.B. Dosimetric deviations in SWAT
A minimum in the EUDr,m results from a high correlation
coefficient of the delivery pattern parallel to the target
motion. If an extremal collimator elongation is opposed by
an elongation in the same direction, an integer number of
collimator sweeps between the two opposing beams will result
in another minimum in EUDr,m. It was shown in Fig. 5
that the manifestation of interplay effects changes in SWAT
from spotlike artifacts, as presented in Fig. 5 (middle) or by
Bortfeld et al.11,12 for IMRT, to widespread underdosed areas
as presented in Fig. 5 (right). Since all treatment plans were
generated with 0◦ collimator angle, the sweeping windows
moved parallel to the direction of gantry motion and caused
dose deviations for target motion perpendicular to the gantry
rotation axis to be on average 0.7% higher than the deviations
resulting from motion parallel to the gantry rotation axis. The
presented approach focuses on dose homogeneity in the PTV,
whereas the CTV is the relevant structure that will affect the
treatment efficiency. For standard IMRT, the location of the
underdosed volume within the PTV remains unknown with
this approach. In the case of SWAT, a nonrobust breathing
period will, provided an unfortunate starting phase is chosen,
generate an underdosed area in the central region of the PTV
[Fig. 5 (right)]. As CTV–PTV margins are usually chosen
symmetrically around the CTV, (Ref. 25) the underdosage
will occur in the CTV.
4.C. Robust treatment planning in SWAT
While the motion amplitude is used to determine the PTV
margin during treatment planning,33 the breathing period is
typically not considered. One option to minimize interplay
effects in SWAT is to increase the increment parameter
to reduce the number of sweeps. The human breathing is
typically between 9 and 23 breathing cycles per minute.36
Provided that the rotational velocity of the gantry does
not exceed Θ̇ ≤ 2π/60 s in combination with the results from
Table I, care should be taken if choosing an increment factor
of ∆Θ= 20◦.
Using multiple arcs with different increment factors or
collimator angles during treatment delivery will further
desynchronize the delivery pattern. For treatment plans, in
which the treatment volume is located laterally, most of
the dose will originate from a subarc around 90◦ or 270◦
gantry angle, where the motion component in AP-direction
is maximal. These cases have to be considered with special
care, since an averaging of opposing beamlets and dosimetric
contributions from beamlets, where the target moves parallel
to the central axis of the beam, will not be present.
For standard IMRT, Jiang et al.14 recommend to use a
low dose rate when treating a moving tumor without any
motion mitigation techniques. The presented approach can
be considered as a quantitative method to obtain the fastest
robust treatment sequence for VMAT with a sweeping window
collimator dynamic. An iterative decrease of the maximum
dose rate can be used to alter the temporal behavior of
the delivery pattern xp. For xt, a realistic target trajectory
can be obtained from 4D-CT data. Due to interfractional
changes in the breathing pattern, it is recommended to test
against additional realistic breathing patterns. This procedure
provides the possibility to produce robust sequences without
having to reoptimize the treatment sequence. As the presented
minima in EUDr,m are typically temporally local, a small
decrease in treatment time will suffice to move out of a
minimum. Chin et al.9 adjusted the increment factors to match
the patient breathing, obtained from 4D-CT data. While this
is the optimum method if the patient breathing trajectory is
known, the method presented in this work does not rely on
an exact knowledge of the target dynamic during treatment
delivery. Although it does not warrant a reduction of safety
margins, it assures a fast convergence to a pure dose blurring
situation.
5. CONCLUSION
With the advent of fast delivery techniques less robust
treatment plans within the human breathing range can be
generated. In SWAT, the correlation coefficient between the
collimator pattern and realistic motion trajectories serves as
an estimate for the plan robustness. By iteratively decreasing
the maximum dose rate, a robust treatment sequence can be
warranted. No degradation of the relative minimum EUD
above 8.0% compared to the static case was found.
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